Posts

HEARTS 2.0: PAHO's 38-Step Pathway for Cardio-Renal Care

Backed by 26 ministries and GRADE evidence, PAHO's new clinical pathway could accelerate access to SGLT2 inhibitors and statins to curb cardiorenal complications. Medscape News Global source https://www.medscape.com/viewarticle/hearts-2-0-pahos-38-step-pathway-cardio-renal-care-2026a1000hk1?src=rss

Older Age Tied to Higher CT Positivity in Abdominal Pain

Older adults visiting the emergency department for abdominal pain have higher risks for CT positivity and hospital admission than younger adults, despite less specific symptoms. Medscape Medical News source https://www.medscape.com/viewarticle/older-age-tied-higher-ct-positivity-abdominal-pain-2026a1000heb?src=rss

Is Venetoclax Retreatment Effective in Relapsed CLL?

Researchers review available clinical evidence for retreatment with venetoclax, alone or in combination, in patients with relapsed chronic lymphocytic leukemia. Medscape Medical News source https://www.medscape.com/viewarticle/venetoclax-retreatment-effective-relapsed-cll-2026a1000he0?src=rss

Interface Lets Paralyzed Patient 'Type' Faster than Ever

A paralyzed patient nearly matched the words per minute the average person can type on their phone, with 95% accuracy. See how brain-computer interface has improved. Medscape Medical News source https://www.medscape.com/viewarticle/new-interface-lets-paralyzed-patient-type-faster-than-ever-2026a1000hd9?src=rss

How to Boost CRC Screening Uptake in the Community

Programs that support patients in the screening process or mail stool test kits to their homes are most effective at boosting colorectal cancer screening rates. Medscape Medical News source https://www.medscape.com/viewarticle/how-boost-crc-screening-uptake-community-2026a1000h3u?src=rss

FDA Approves Bulevirtide for Hepatitis Delta Virus

Bulevirtide (Hepcludex; Gilead Sciences, Inc.) is the first FDA-approved treatment for chronic hepatitis delta virus infection. Medscape Medical News source https://www.medscape.com/viewarticle/fda-approves-bulevirtide-hepatitis-delta-virus-2026a1000h3x?src=rss